Turkiye Klinikleri Journal of Pediatrics

.: REVIEW
Koryoamniyonit ve Fetal Etkileri
Chorioamnionitis and Its Fetal Effects
Hakan ONGUNa, Kıymet ÇELİKa, Nihal OYGÜRa
aAkdeniz Üniversitesi Tıp Fakültesi, Yenidoğan BD, Antalya, TÜRKİYE
Turkiye Klinikleri J Pediatr. 2020;29(3):175-86
doi: 10.5336/pediatr.2020-76142
Article Language: TR
Full Text
ÖZET
 Koryoamniyonit; koryon, amniyotik sıvı, umbilikal kordon ve fetal membranların 20. gestasyon haftasından sonra oluşan enfeksiyon ve/veya inflamasyondur. Çoğunluğu subklinik olup, plasentanın retrospektif histopatolojik analizi ile tanımlanabilmektedir. Enfeksiyonun en sık gelişme şekli, erken membran rüptürü sonrası bakterilerin alt genital sistemden asendan yolla serviks ve koryodesiduel alan üzerinden koryoamniyonik zarı geçerek, amniyotik sıvıya ve fetüse ulaşmasıdır. Ancak bakteriler, membran rüptüre olmadan da hematojen yolla, periton boşluğundan fallopyan tüplerine geçerek veya invaziv işlemler sırasında inoküle edilerek fetüse ulaşabilir. Fetüse geçiş yolu ise fetal damarlara invaze olarak koryovaskülitis veya amniyotik boşluğa geçerek amniyonit yapan bakterilerin, fetal solunum yolu, gastrointestinal yol, timpanik zar ya da konjonktiva gibi mukoz membranlara ulaşımıdır. En sık etkenlerin Ureaplasma suşları (U. parvum ve U. urealyticum) ve genital mikoplazmalar (Mycoplasma hominis) olduğu bilinmektedir; ancak tanımlanan bir mikroorganizma olmadan da gerçekleşebilir. Fetal inflamatuar yanıt sendromu, koryoamniyonit nedeni ile fetal immün sistemin sistemik aktivasyonu ve buna bağlı fetal organların çoğunda ortaya çıkan inflamasyon/enfeksiyon bulgularının toplamıdır. Fetal plazma, interlökin-6 düzey yüksekliği (>11 pg/mL) ve histolojik olarak koryoamniyonit/funizit saptanması bulgularından en az birinin mevcut olması ile tanımlanabilmektedir. Fetal inflamatuar yanıt sendromu, fetüsün beyin, akciğer, böbrek ve kalbine olumsuz etkileriyle çoklu organ harabiyetine sebep olmaktadır.

Anahtar Kelimeler: Koryoamniyonit; fetal inflamatuar yanıt
ABSTRACT
 Chorioamnionitis is characterized by infection and/or inflammation of the chorion, amniotic fluid, umbilicus and the fetal membranes occuring after the 20th week of gestation. A large proportion of cases are subclinical and not diagnosed until retrospective analysis of the placenta. The most widely accepted route is, ascending of microorganisms from the maternal lower genital tract into the choriodecidual space and crossing the chorioamnionic membrane, thereby reaching the amniotic fluid and fetus, after rupture of membranes. However microorganisms can also reach the amniotic fluid without rupture. The routes to the fetus may be the migration of organisms from the maternal bloodstream across the placenta, anterograde infection from peritoneum via the fallopian tubes, iatrogenic inoculation during invasive procedures. For fetal involvement, bacterias invade the fetal vessels (choriovasculitis) or cross the amnion (amnionitis) into the amniotic cavity, reach the fetus through the respiratory or gastrointestinal tract, or through the mucous membranes (tympanic or conjunctiva). Ureaplasma species (U. parvum, U. urealyticum) and genital mycoplasmas (Mycoplasma hominis) are the most common microorganisms isolated from the amniotic fluid however, it may also occur in the absence of demonstrable microorganisms. The fetal inflammatory response syndrome is a condition characterized by systemic activation of the fetal innate immune system and multiple organ dysfunction due to infection/inflammation. It can be diagnosed with the detection of at least one of the findings of high interleukin-6 concentrations (>11 pg/mL) in fetal plasma and the histological chorioamnionitis/funisitis. Fetal inflammatory response syndrome results in multiorgan disfunction with its negative effects on fetal brain, lung, kidneys and heart.

Keywords: Chorioamnionitis; fetal inflammatory response
REFERENCES:
  1. Peng CC, Chang JH, Lin HY, Cheng PJ, Su BH. Intrauterine inflammation, infection, or both (Triple I): a new concept for chorioamnionitis. Pediatr Neonatol. 2018;59(3):231-37. [Crossref]  [PubMed] 
  2. Romero R, Chaemsaithong P, Korzeniewski SJ, Tarca AL, Bhatti G, Xu Z, et al. Clinical chorioamnionitis at term II: the intra-amniotic inflammatory response. J Perinat Med. 2016;44(1):5-22.
  3. Romero R, Miranda J, Chaemsaithong P, Chaiworapongsa T, Kusanovic JP, Dong Z, et al. Sterile and microbial-associated intra-amniotic inflammation in preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med. 2015;28(12):1394-409. [Crossref]  [PubMed]  [PMC] 
  4. Gupta T, Singh S, Gupta S, Gupta N. Normal implantation, placentation, and fetal development. In: Mehta S, Gupta B, eds. Recurrent Pregnancy Loss. 1st ed. Singapore: Springer; 2018. p.13-40. http://doi.org-443.webvpn.fjmu.edu.cn/10.1007/978-981-10-7338-0_2 Online ISBN: 978-981-10-7338-0 [Crossref] 
  5. Sweeney EL, Dando SJ, Kallapur SG, Knox CL. The human Ureaplasma species as cusative agents of chorioamnionitis. Clin Microbiol Rev. 2017;30(1):349-79. [Crossref]  [PubMed]  [PMC] 
  6. Higgins RD, Saade G, Polin RA, Grobman WA, Buhimschi IA, Watterberg K, et al. Evaluation and management of women and newborns with a maternal diagnosis of chorioamnionitis: summary of a workshop. Obstet Gynecol. 2016;127(3):426-36. [Crossref]  [PubMed]  [PMC] 
  7. Randis TM, Polin RA, Saade G. Chorioamnionitis: time for a new approach. Curr Opin Pediatr. 2017;29(2):159-64. [Crossref]  [PubMed] 
  8. Greenberg MB, Anderson BL, Schulkin J, Norton ME, Aziz N. A first look at chorioamnionitis management practice variation among US obstetricians. Infect Dis Obstet Gynecol. 2012;2012: 628362. [Crossref]  [PubMed]  [PMC] 
  9. Kim CJ, Romero R, Chaemsaithong P, Chaiyasit N, Yoon BH, Kim YM. Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical significance. Am J Obstet Gynecol. 2015;213(4 Suppl):S29-52. [Crossref]  [PubMed]  [PMC] 
  10. Kachikis A, Eckert LO, Walker C, Bardají A, Varricchio F, Lipkind HS, et al; Brighton Collaboration Chorioamnionitis Working Group. Chorioamnionitis: case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2019;37(52):7610-22. [Crossref]  [PubMed]  [PMC] 
  11. Smith MM, Daifotis HA, DeNoble AE, Dotters-Katz SK. Using the new definition of intraamniotic infection-is there morbidity among the women left out? J Matern Fetal Neonatal Med. 2020:1-5. [Crossref]  [PubMed] 
  12. Villar J, Papageorghiou AT, Knight HE, Gravett MG, Iams J, Waller SA, et al. The preterm birth syndrome: a prototype phenotypic classification. Am J Obstet Gynecol. 2012;206(2):119-23. [Crossref]  [PubMed] 
  13. Newton ER. Preterm labor, preterm premature rupture of membranes, and chorioamnionitis. Clin Perinatol. 2005;32(3):571-600. [Crossref]  [PubMed] 
  14. Lee SM, Lee KA, Kim SM, Park CW, Yoon BH. The risk of intra-amniotic infection, inflammation and histologic chorioamnionitis in term pregnant women with intact membranes and labor. Placenta. 2011;32(7):516-21. [Crossref]  [PubMed] 
  15. Menon R, Taylor RN, Fortunato SJ. Chorioamnionitis--a complex pathophysiologic syndrome. Placenta. 2010;31(2):113-20. [Crossref]  [PubMed] 
  16. Sabogal CPC, Fonseca J, García-Perdomob HA. Validation of diagnostic tests for histologic chorioamnionitis: systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2018;228:13-26. [Crossref]  [PubMed] 
  17. Palmsten K, Nelson KK, Laurent LC, Park S, Chambers CD, Parast MM. Subclinical and clinical chorioamnionitis, fetal vasculitis, and risk for preterm birth: a cohort study. Placenta. 2018;67:54-60. [Crossref]  [PubMed]  [PMC] 
  18. Liu Y, Liu Y, Du C, Zhang R, Feng Z, Zhang J. Diagnostic value of amniotic fluid inflammatory biomarkers for subclinical chorioamnionitis. Int J Gynecol Obstet. 2016;134(2):160-4. [Crossref]  [PubMed] 
  19. Conti N, Torricelli M, Voltolini C, Vannuccini S, Clifton VL, Bloise E, et al. Term histologic chorioamnionitis: a heterogeneous condition. Eur J Obstet Gynecol Reprod Biol. 2015;188:34-8. [Crossref]  [PubMed] 
  20. Oh KJ, Romero R, Park JY, Hong JS, Yoon BH. The earlier the gestational age, the greater the intensity of the intra-amniotic inflammatory response in women with preterm premature rupture of membranes and amniotic fluid infection by Ureaplasma species. J Perinat Med. 2019; 47(5):516-27. [Crossref]  [PubMed]  [PMC] 
  21. Romero R, Kim YM, Pacora P, Kim CJ, Benshalom-Tirosh N, Jaiman S, et al. The frequency and type of placental histologic lesions in term pregnancies with normal outcome. J Perinat Med. 2018;46(6):613-30. [Crossref]  [PubMed]  [PMC] 
  22. Romero R, Espinoza J, Gonçalves LF, Kusanovic JP, Friel L, Hassan S. The role of inflammation and infection in preterm birth. Semin Reprod Med. 2007;25(1):21-39. [Crossref]  [PubMed] 
  23. Morency AM, Bujold E. The effect of second-trimester antibiotic therapy on the rate of preterm birth. J Obstet Gynaecol Can. 2007;29(1):35-44. [Crossref] 
  24. Galán Henríquez GM, García-Mu-oz Rodrigo F. Chorioamnionitis and neonatal morbidity: current perspectives. Res Reports Neonatol. 2017;7:41-52. [Crossref] 
  25. Glaser K, Gradzka-Luczewka A, Szymankiewicz-Breborowicz M, Kawczynska-Leda N, Henrich B, Waaga-Gasser AM, et al. Perinatal Ureaplasma exposure is associated with increased risk of late onset sepsis and imbalanced inflammation in preterm infants and may add to lung injury. Front Cell Infect Microbiol. 2019;9:68. [Crossref]  [PubMed]  [PMC] 
  26. Prince AL, Ma J, Kannan PS, Alvarez M, Gisslen T, Harris RA, et al. The placental microbiome is altered among subjects with spontaneous preterm birth with and without chorioamnionitis. Am J Obstet Gynecol. 2016;214(5):627.e1-627.e16. [Crossref]  [PubMed]  [PMC] 
  27. Vancutsem E, Faron G, Foulon W, Naessens A. Genital tract colonization with Ureaplasma spp. and its association with abnormal vaginal flora. J Med Microbiol. 2015;64(6):654-6. [Crossref]  [PubMed] 
  28. Mavort M, Ke?e D, Kotar T, Kmet N, Miljković J, ?oba B, et al. Ureaplasma parvum and Ureaplasma urealyticum detected with the same frequency among women with and without symptoms of urogenital tract infection. Eur J Clin Microbiol Infect Dis. 2015;34(6):1237-45. [Crossref]  [PubMed] 
  29. Romero R, Mazor M. Infection and preterm labor. Clin Obstet Gynecol.1988;31(3):553-84. [Crossref]  [PubMed] 
  30. Gotsch F, Romero R, Kusanovic JP, Mazaki-Tovi S, Pineles BL, Erez O, et al. The fetal inflammatory response syndrome. Clin Obstet Gynecol. 2007;50(3):652-83. [Crossref]  [PubMed] 
  31. Oh JW, Park CW, Moon KC, Park JS, Jun JK. The relationship among the progression of inflammation in umbilical cord, fetal inflammatory response, early-onset neonatal sepsis, and chorioamnionitis. PLoS One. 2019;14(11):e0225328. [Crossref]  [PubMed]  [PMC] 
  32. McNamara MF, Wallis T, Qureshi F, Jacques SM, Gonik B. Determining the maternal and fetal cellular immunologic contributions in preterm deliveries with clinical or subclinical chorioamnionitis. Infect Dis Obstet Gynecol. 1997;5(4):273-9. [Crossref] 
  33. Redline RW, Faye-Petersen O, Heller D, Qureshi F, Savell V, Vogler C; Society for Pediatric Pathology, Perinatal Section, Amniotic Fluid Infection Nosology Committee. Amniotic infection syndrome: nosology and reproducibility of placental reaction patterns. Pediatr Dev Pathol. 2003;6(5):435-48. [Crossref]  [PubMed] 
  34. Redline RW. Classification of placental lesions. Am J Obstet Gynecol. 2015;213(4 Suppl):S21-8. [Crossref]  [PubMed] 
  35. Redline RW. Inflammatory response in acute chorioamnionitis. Semin Fetal Neonatal Med. 2012;17(1):20-5. [Crossref]  [PubMed] 
  36. Kim CJ, Yoon BH, Kim M, Park JO, Cho SY, Chi JG. Histo-topographic distribution of acute inflammation of the human umbilical cord. Pathol Int. 2001;51(11):861-5. [Crossref]  [PubMed] 
  37. Kim CJ, Yoon BH, Romero R, Moon JB, Kim M, Park SS, et al. Umbilical arteritis and phlebitis mark different stages of the fetal inflammatory response. Am J Obstet Gynecol. 2001;185(2):496-500. [Crossref]  [PubMed] 
  38. Hecht JL, Allred EN, Kliman HJ, Zambrano E, Doss BJ, Husain A, et al; Elgan Study Investigators. Histological characteristics of singleton placentas delivered before the 28th week of gestation. Pathology. 2008;40(4):372-6. [Crossref]  [PubMed]  [PMC] 
  39. Corbett NP, Blimkie D, Ho KC, Cai B, Sutherland DP, Kallos A, et al. Ontogeny of toll-like receptor mediated cytokine responses of human blood mononuclear cells. PLoS One. 2010;5(11):e15041. [Crossref]  [PubMed]  [PMC] 
  40. Kollmann TR, Crabtree J, Rein-Weston A, Blimkie D, Thommai F,Wang XY, et al. Neonatal innate TLR-mediated responses are distinct from those of adults. J Immunol. 2009;183(11):7150-60. [Crossref]  [PubMed]  [PMC] 
  41. Stinson LF, Payne MS, Keelan JA. Placental and intra-amniotic inflammation are associated with altered fetal immune responses at birth. Placenta. 2019;85:15-23. [Crossref]  [PubMed] 
  42. Seong HS, Lee SE, Kang JH, Romero R, Yoon BH. The frequency of microbial invasion of the amniotic cavity and histologic chorioamnionitis in women at term with intact membranes in the presence or absence of labor. Am J Obstet Gynecol. 2008;199(4):375.e1-5. [Crossref]  [PubMed]  [PMC] 
  43. Galask RP, Varner MW, Petzold CR, Wilbur SL. Bacterial attachment to the chorioamniotic membranes. Am J Obstet Gynecol. 1984;148(7):915-28. [Crossref] 
  44. Romero R, Sirtori M, Oyarzun E, Avila C, Mazor M, Callahan R, et al. Infection and labor. V. Prevalence, microbiology, and clinical significance of intraamniotic infection in women with preterm labor and intact membranes. Am J Obstet Gynecol. 1989;161(3):817-24. [Crossref] 
  45. Musilova I, Andrys C, Drahosova M, Soucek O, Stepan M, Bestvina T, et al. Intraamniotic inflammation and umbilical cord blood interleukin-6 concentrations in pregnancies complicated by preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med. 2016;30(8):900-10. [Crossref]  [PubMed] 
  46. Chiesa C, Pacifico L, Natale F, Hofer N,Osborn JF, Resch B. Fetal and early neonatal interleukin-6 response. Cytokine. 2015;76(1):1-12. [Crossref]  [PubMed] 
  47. Yoon BH, Romero R, Park JS, Kim M, Oh SY, Kim CJ, et al. The relationship among inflammatory lesions of the umbilical cord (funisitis), umbilical cord plasma interleukin 6 concentration, amniotic fluid infection, and neonatal sepsis. Am J Obstet Gynecol. 2000;183(5):1124-9. [Crossref]  [PubMed] 
  48. Mikołajczyk M, Wirstlein P, Adamczyk M, Skrzypczak J, Wender-Ożegowska E. Value of cervicovaginal fluid cytokines in prediction of fetal inflammatory response syndrome in pregnancies complicated with preterm premature rupture of membranes (pPROM). J Perinat Med. 2020;48(3):249-55. [Crossref]  [PubMed] 
  49. Romero R, Gomez R, Ghezzi F, Yoon BH, Mazor M, Edvin SS, et al. A fetal systemic inflammatory response is followed by the spontaneous onset of preterm parturition. Am J Obstet Gynecol. 1998;179(1):186-93. [Crossref] 
  50. Sciaky-Tamir Y, Hershkovitz R, Mazor M, Shelef I, Erez O. The use of imaging technology in the assessment of the fetal inflammatory response syndrome-imaging of the fetal thymus. Prenat Diag. 2015;35(5):413-9. [Crossref]  [PubMed] 
  51. Mastrolia SA, Erez O, Loverro G, Di Naro E, Weintraub AY, Tirosh D, et al. Ultrasonographic approach to diagnosis of fetal inflammatory response syndrome: a tool for at-risk fetuses? Am J Obstet Gynecol. 2016;215(1):9-20. [Crossref]  [PubMed] 
  52. Christensen KK. Infection as a predominant cause of perinatal mortality. Obstet Gynecol. 1982;59(4):499-508.
  53. Agrawal V, Hirsch E. Intrauterine infection and preterm labor. Semin Fetal Neonatal Med. 2012;17(1):12-9. [Crossref]  [PubMed]  [PMC] 
  54. Park H, Park KH, Kim YM, Kook SY, Jeon SJ, Yoo HN. Plasma inflammatory and immune proteins as predictors of intra-amniotic infection and spontaneous preterm delivery in women with preterm labor: a retrospective study. BMC Pregnancy Childbirth. 2018:18(1):146. [Crossref]  [PubMed]  [PMC] 
  55. Yoon BH, Romero R, Moon JB, Shim SS, Kim M, Kim G, et al. Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes. Am J Obstet Gynecol. 2001;185(5):1130-6. [Crossref]  [PubMed] 
  56. Sung JH, Choi SJ, Oh SY, Roh CR, Kim JH. Revisiting the diagnostic criteria of clinical chorioamnionitis in preterm birth. BJOG. 2017;124(5):775-83. [Crossref]  [PubMed] 
  57. Sprong KE, Mabenge M, Wright CA, Govender S. Ureaplasma species and preterm birth: cur­rent perspectives. Crit Rev Microbiol. 2020;46(2):169-81. [Crossref]  [PubMed] 
  58. Speer CP. Inflammation and bronchopulmonary dysplasia: a continuing story. Semin Fetal Neonatal Med. 2006;11(5):354-62. [Crossref]  [PubMed] 
  59. Jobe AH. Antenatal associations with lung maturation and infection. J Perinatol. 2005;25 Suppl 2:S31-5. [Crossref]  [PubMed] 
  60. Sarno L, Corte LD, Saccone G, Sirico A, Raimondi F, Zullo F, et al. Histological chorioamnionitis and risk of pulmonary complications in preterm births: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2019:1-10. [Crossref]  [PubMed] 
  61. Viscardi RM. Perinatal inflammation and lung injury. Semin Fetal Neonatal Med. 2012;17(1):30-5. [Crossref]  [PubMed]  [PMC] 
  62. Park CW, Park JS, Jun JK, Yoon BH. Mild to moderate, but not minimal or severe, acute histologic chorioamnionitis or intra-amniotic inflammation is associated with a decrease in respiratory distress syndrome of preterm newborns without fetal growth restriction. Neonatology. 2015;108(2):115-23. [Crossref]  [PubMed] 
  63. Kallapur SG, Willet KE, Jobe AH, Ikegami M, Bachurski CJ. Intra-amniotic endotoxin: chorioamnionitis precedes lung maturation in preterm lambs. Am J Physiol Lung Cell Mol Physiol. 2001;280(3):L527-36. [Crossref]  [PubMed] 
  64. Shi Z, Vasquez-Vivar J, Luo K, Yan Y, Northington F, Mehrmohammadi M, et al. Ascending lipopolysaccharide-induced intrauterine inflammation in near-term rabbits leading to newborn neurobehavioral deficits. Dev Neurosci. 2018;40(5-6):534-46. [Crossref]  [PubMed] 
  65. Rangon CM, Schang AL, Van Steenwinckel J, Schwendimann L, Lebon S, Fu T, et al. Myelination induction by a histamine H3 receptor antagonist in a mouse model of preterm white matter injury. Brain Behav Immun. 2018;74:265-76. [Crossref]  [PubMed] 
  66. Shi Z, Ma L, Luo K, Bajaj M, Chawla S, Natarajan G, et al. Chorioamnionitis in the development of cerebral palsy: a meta-analysis and systematic review. Pediatrics. 2017;139(6):e20163781. [Crossref]  [PubMed]  [PMC] 
  67. Gussenhoven R, Westerlaken RJJ, Ophelders DRMG, Jobe AH, Kemp MW, Kallapur SG, et al. Chorioamnionitis, neuroinflammation, and injury: timing is key in the preterm ovine fetus. J Neuroinflammation. 2018;15(1):113. [Crossref]  [PubMed]  [PMC] 
  68. Romero R, Espinoza J, Gonçalves LF, Gomez R, Medina L, Silva M, et al. Fetal cardiac dysfunction in preterm premature rupture of membranes. J Matern Fetal Neonatal Med. 2004;16(3):146-57. [Crossref] 
  69. Vanderbroucke L, Doyen M, Lous ML, Beuchée A, Loget P, Carrault G, et al. Chorioamnionitis following preterm premature rupture of membranes and fetal heart rate variability. Plos One. 2017;12(9): e0184924. [Crossref]  [PubMed]  [PMC] 
  70. Mitchell T, Macdonald JW, Srinouanpranchanh S, Bammler TK, Merillat S, Boldenow E, et al. Evidence of cardiac involvement in the fetal inflammatory response syndrome: disruption of gene networks programming cardiac development in nonhuman primates. Am J Obstet Gynecol. 2018;218(4):438.e1-438.e16. [Crossref]  [PubMed]  [PMC] 
  71. Di Naro E, Cromi A, Ghezzi F, Giocolano A, Caringella A, Loverro G. Myocardial dysfunction in fetuses exposed to intraamniotic infection: new insights from tissue Doppler and strain imaging. Am J Obstet Gynecol. 2010;203(5):459.e1-7. [Crossref]  [PubMed] 
  72. Tonni G, Rosignoli L, Cariati E, Martins WP, Miyague AH, Bruns RF, et al. Fetal thymus: visualization rate and volume by integrating 2D- and 3D-ultrasound during 2nd trimester echocardiography. J Matern Fetal Neonatal Med. 2016;29(14):2223-8. [Crossref]  [PubMed] 
  73. Kuban JD, Allred EN, Leviton A. Thymus involution and cerebral white matter damage in extremely low gestational age neonates. Biol Neonate. 2006;90(4):252-7. [Crossref]  [PubMed] 
  74. Ferber A, Minior VK, Bornstein E, Divon MY. Fetal "nonreassuring status" is associated with elevation of nucleated red blood cell counts and interleukin-6. Am J Obstet Gynecol. 2005;192(5):1427-9. [Crossref]  [PubMed] 
  75. Nakamura T, Hatanaka D, Kusakari M, Kashima K, Takizawa Y, Takahashi H, et al. Neonatal leukemoid reaction with fetal inflammatory response syndrome is associated with elevated serum granulocyte colony stimulating factor and interleukin-6. Tohoku J Exp Med. 2018; 244(2):145-9. [Crossref]  [PubMed] 
  76. Romero R, Savasan ZA, Chaiworapongsa T, Berry SM, Kusanovic JP, Hassan SS, et al. Hematologic profile of the fetus with systemic inflammatory response syndrome. J Perinat Med. 2011;40(1):19-32. [Crossref] 
  77. Yoon BH, Kim YA, Romero R, Kim JC, Park KH, Kim MH, et al. Association of oligohydramnios in women with preterm premature rupture of membranes with an inflammatory response in fetal, amniotic, and maternal compartments. Am J Obstet Gynecol. 1999;181(4):784-8. [Crossref] 
  78. Pan X, Zhang D, Nguyen DN, Wei W, Yu X, Gao F, et al. Postnatal gut immunity and microbiota development is minimally affected by prenatal inflammation in preterm pigs. Front Immunol. 2020;11:420. [Crossref]  [PubMed]  [PMC] 
  79. Been JV, Lievense S, Zimmermann LJI, Kramer BW, Wolfs TGAM. Chorioamnionitis as a risk factor for necrotizing enterocolitis: a systematic review and meta-analysis. J Pediatr. 2013;162(2):236-42.e2. [Crossref]  [PubMed] 
  80. Been JV, Rours IGIJG, Kornelisse RF, Lima Passos V, Kramer BW, Schneider TAJ, et al. Histologic chorioamnionitis, fetal involvement, and antenatal steroids: effects on neonatal outcome in preterm infants. Am J Obstet Gynecol. 2009;201(6):587e1-8. [Crossref]  [PubMed] 
  81. Kim YM, Romero R, Chaiworapongsa T, Espinoza J, Mor G, Kim CJ. Dermatitis as a component of the fetal inflammatory response syndrome is associated with activation of Toll-like receptors in epidermal keratinocytes. Histopathology. 2006;49(5):506-14. [Crossref]  [PubMed]  [PMC] 
  82. Yoon BH, Romero R, Jun JK, Maymon E, Gomez R, Mazor M, et al. An increase in fetal plasma cortisol but not dehydroepiandrosterone sulfate is followed by the onset of preterm labor in patients with preterm premature rupture of the membranes. Am J Obstet Gynecol. 1998;179(5):1107-14. [Crossref] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com